Dear AACE Community,

As President of AACE, it is my privilege to share with you a summary of the major actions and key decisions made during the AACE Board of Directors and Board of Trustees meeting on October 25-26, 2024. These updates reflect our unwavering commitment to shaping the future of endocrinology and strengthening the support we provide to our community, our members, and the patients they serve.

AACE Journals

Beginning in 2025, AACE Endocrine Practice journal will transition to a fully digital format. The fully digital format will enhance the opportunities for AACE members to have their important research published by AACE and will allow for greater flexibility and timeliness, ensuring that cutting-edge science reaches our community faster. 

In the Spring 2025, AACE Clinical Case Reports (ACCR)  journal will include Open Access original research and reviews, alongside case reports and visual content. ACCR will be rebranded with a new name and identity to reflect its expanded scope that emphasizes the scientific soundness of endocrinology to better serve the scientific community with a broader range of endocrinology content. More exciting details coming soon!

FACE Application Committee

• The Board approved removing the letter of explanation for membership lapse from the   FACE reinstatement process. 

Clinical Practice Guidelines oversight Committee

• The Board approved submission of the “AACE Consensus Statement:  Management of Multiple Endocrine Neoplasia, Type 1”  to Endocrine Practice for Publication. 

International Growth

AACE is growing in the international regions. Three key areas noted are (i) membership and FACE expansion and retention, (ii) education and professional development, and (iii) global expansion through collaboration.  AACE is excited to announce a new APAC Advisory Board that will help AACE build out a road map for the APAC region.  In addition, there is development of a new AACE global forum which will have sessions from India, Pakistan and Mexico at the upcoming Annual Meeting in Orlando. 

Nominating Committee

The Board approved the Nominating Committee Slate for Officers in 2025 (one-year terms beginning January 1, 2025 through December 31, 2025) and the Slate of Officers has been provided to AACE Membership for review in accordance with AACE Bylaws.  The 2025 Slate of Officers is  as follows:

• President-Elect: Dr. Dace L. Trence 
• Treasurer: Dr. Leslie S. Eldeiry 
• Secretary: Dr. Kenneth E. Izuora

The Board approved the Nominating Committee Slate for five (5) Board positions in 2025 (three-year terms beginning January 1, 2025 through December 31, 2025)  and the Slate for five (5) Board positions has been provided to AACE Membership for review in accordance with AACE Bylaws.  The 2025 Slate for the five (5) Board positions is as follows:

• Dr. Rodolfo J. Galindo, MD, FACE – Miami, FL
• Dr. Geetha Gopalakrishnan, MD, FACE – Pawtucket, RI (Incumbent)
• Dr. Rifka Schulman-Rosenbaum, MD, FACE – New Hyde Park, NY
• Dr. Elias S. Siraj, MD, FACP, FACE – Norfolk, VA (Incumbent)
• Dr. Mihail Zilbermint, MD, FACE – Bethesda, MD

The Board approved the Nominating Committee Slate for two (2) Board positions in 2025 (one-year terms beginning January 1, 2025 through December 31, 2025) and the Slate for two (2) Board positions has been provided to AACE Membership for review in accordance with AACE Bylaws. The 2025 Slate for two (2) Board positions is  as follows:

• Dr. Rajesh Garg, MD – Torrence, CA
• Dr. Joanna Miragaya, MD, PhD, FACE – Marietta, GA 

The following outgoing Board members were recognized and presented a plaque for their service:

• Dr. S. Sethu K. Reddy – Board Member 2003 through 2006 and 2017; Officer 2018 through 2024
• Dr. Gary W. Edelson – Board Member 2017 through 2024
• Dr. Young – Board Member 2021-2024
• Dr. Leung – Borad Member 2021-2024

Advocacy Committee

The AACE Advocacy Committee has been busy with sign-on letters. A letter was submitted to CMS Administrator, Chiquita Brooks-LaSure expressing concern with the CY2025 Medicare Physician Fee Schedule (MPFS) addressing specific concerns such as the 2.8% decrease in the conversion factor, reimbursement challenges faced by endocrinologists in private non-facility based practices for Radiofrequency Ablation of thyroid nodules, the inability of clinicians to bill G2211 alongside modifier 25 when performing a procedure or providing other services, and the mis-valuation of codes 10005 and 10021 ultrasound guided FNA procedures. We are also supporting legislation that affects our patients and a bill in congress that supports not funding schools who discontinue DE&I.

Through these actions, we reaffirm our mission to elevate the practice of clinical endocrinology to improve global health. 

Sincerely,

Susan L. Samson, MD, PhD, FRCPC, FACE

AACE President